Amel Mézlini

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

Tadeusz Robak, Jie Jin, Halyna Pylypenko et al. · The Lancet Oncology · 2018 · 132 citations

Hematological Malignancy, Frontline Bortezomib, Lymphoid Neoplasia +13

Significant association between interleukin-17A polymorphism and colorectal cancer

Inés Omrane, Raja Marrakchi, Olfa Baroudi et al. · Tumor Biology · 2014 · 56 citations

Significant association between IL23R and IL17F polymorphisms and clinical features of colorectal cancer

Inés Omrane, Olfa Baroudi, Karim Bougatef et al. · Immunology Letters · 2014 · 44 citations

Il17f Polymorphisms, Cancer Epidemiology, Immunology +9

Inflammatory breast cancer in Tunisia in the era of multimodality therapy

K. Mrad, Amel Mézlini, Mouna Ayadi Ouarda et al. · Annals of Oncology · 2007 · 43 citations

Breast Oncology, Oncology, Inflammatory Breast Cancer +5

Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers

O. Zidi, Nessrine Souai, Henda Raies et al. · Molecules · 2021 · 42 citations · Full text